Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Astrazeneca Plc (AZN.L)
AstraZeneca Announces Approval Of Saphnelo In The EU
12/16/2025 2:26:27 AM
AstraZeneca: Saphnelo Approved In EU For SC Self-administration As New Pre-filled Pen For Systemic Lupus Erythematosus
12/16/2025 2:17:32 AM
AstraZeneca And Daiichi Sankyo: Enhertu + Pertuzumab Approved In US For 1st-line Treatment With HER2-positive Metastatic Breast Cancer
12/16/2025 2:05:31 AM
AstraZeneca : ENHERTU Combination Approved In US For 1st-Line HER2-Positive Metastatic Breast Cancer
12/15/2025 10:27:03 PM
AstraZeneca Hypertension Drug Baxdrostat Wins FDA Priority Review
12/2/2025 10:39:55 AM
FDA Accepts AstraZeneca’s Baxdrostat NDA For Priority Review In Hard-to-Control Hypertension
12/2/2025 9:22:38 AM
AstraZeneca Announces Approval Of Imfinzi In The US
11/26/2025 2:26:47 AM
AstraZeneca: Imfinzi Approved In US For Patients With Early Gastric And Gastroesophageal Cancers
11/26/2025 2:03:10 AM
AstraZeneca To Invest $2 Billion In Maryland Manufacturing Expansion
11/21/2025 11:11:32 PM
AstraZeneca Plans $2 Bln Manufacturing Investment In Maryland
11/21/2025 3:37:59 PM
AstraZeneca: Alexion's Koselugo Gets FDA Approval For Adults With Neurofibromatosis Type 1
11/20/2025 2:42:57 AM
AstraZeneca: Koselugo Approved In US For Adults With Neurofibromatosis Type 1
11/20/2025 2:06:53 AM
AstraZeneca's Baxdrostat Achieves Major Breakthrough In Hypertension Treatment In Phase III Trial
11/9/2025 7:46:42 PM
AstraZeneca Reports Positive Phase III Results For Fasenra In Hypereosinophilic Syndrome
11/7/2025 9:31:33 AM
AstraZeneca’s FASENRA Shows Significant Benefit In Delaying Flares In Hypereosinophilic Syndrome In Phase III Trial
11/7/2025 9:06:29 AM
Axsome Therapeutics Agrees To Obtain Exclusive Global Rights To AZD7325 From AstraZeneca
11/6/2025 7:08:20 AM
AstraZeneca Q3 25 Earnings Conference Call At 8:00 AM ET
11/6/2025 7:00:22 AM
AstraZeneca Q3 Results Climb, Top Estimate; Backs FY25 Outlook
11/6/2025 2:47:18 AM
AstraZeneca Q3 Reported EPS $1.64; Core EPS $2.38
11/6/2025 2:04:20 AM
Daiichi Sankyo And AstraZeneca Initiate DESTINY-Lung06 Trial For Metastatic NSCLC
10/30/2025 9:03:42 PM
1
2
3
Next
»